2018 Virtual Symposium (CME concluded): Advances in HFpEF: Addressing Diagnostic and Treatment Challenges

Prognosis and treatment of HF patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF.

To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to manage HFpEF. This 2018 virtual symposium activity will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.

Diagnosis of HFpEF

Presenter: JoAnn Lindenfeld, MD

The Current State of Pharmacotherapies

Presenter: Keith C. Ferdinand, MD, FACC, FAHA

Decreasing Hospital Readmission Rates for HFpEF Patients

Presenter: Alanna A. Morris, MD, MSc

Audience Q&A

Chairperson: JoAnn Lindenfeld, MD

Presenter: Keith C. Ferdinand, MD, FACC, FAHAAlanna A. Morris, MD, MSc